Julie Westerlin Kjeldsen

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite et al. · Nature Medicine · 2021 · 197 citations · Full text

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

Marco Donia, Rikke Andersen, Julie Westerlin Kjeldsen et al. · Cancer Research · 2015 · 124 citations

T-regulatory Cell, Immunology, Immune Regulation +27

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy

Rikke Andersen, Marie Christine Wulff Westergaard, Julie Westerlin Kjeldsen et al. · Cancer Immunology Research · 2018 · 75 citations · Full text

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

Rikke Andersen, Troels Holz Borch, Arianna Draghi et al. · Annals of Oncology · 2018 · 75 citations · Full text

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

Marie Christine Wulff Westergaard, Rikke Andersen, Chloé Chong et al. · British Journal of Cancer · 2019 · 68 citations · Full text